Breast Cancer Survivors: Who Benefits From Weight-Loss Meds? Will Pass + + + +

https://www.medscape.com/viewarticle/breast-cancer-survivors-who-benefits-weight-loss-meds-2026a1000tdj?src= Preschoolers With Cancer Show Below-Average Motor Function, Muscle Strength at Diagnosis https://www.medscape.com/viewarticle/preschoolers-cancer-show-below-average-motor-function-muscle-2026a1000tcy?src= Preschool children newly diagnosed with cancer demonstrated clinically significant impairments in gross motor function, muscle strength, and functional level. More than three-quarters showed below-average or worse performance in locomotion, and 69% scored below average in functional mobility. Bisphosphonates Tied to Lower Mortality in HR+ Breast Cancer Edited by Katie Lennon https://www.medscape.com/viewarticle/bisphosphonates-tied-lower-mortality-hr-breast-cancer-2026a1000t8b?src= Bisphosphonate (BP) use for at least 1 year after breast cancer diagnosis was associated with reduced all-cause mortality and breast cancer-specific mortality in women with hormone receptor-positive (HR+) breast cancer. Among those with triple-negative breast cancer (TNBC), pre-diagnostic BP use and continued use across both pre- and post-diagnosis periods, on the other hand, were linked to more than tripled recurrence risk and more than doubled breast cancer-specific mortality risk, the new study showed. Does Maintenance Therapy Improve Survival After First-Line Bevacizumab Treatment in Metastatic Colorectal Cancer? Edited by Gargi Mukherjee https://www.medscape.com/viewarticle/does-maintenance-therapy-improve-survival-after-first-line-2026a1000sy8?src= Maintenance therapy was associated with longer overall survival (OS) than active surveillance in patients with metastatic colorectal cancer (mCRC) who achieved disease control after first-line bevacizumab-based combination chemotherapy. However, this association was not maintained after adjustment for baseline prognostic factors, suggesting that baseline differences may have contributed to the observed survival advantage.